Loading...
XHKG
2325
, Last price  
HKD
Name

Yunkang Group Ltd

Chart & performance

D1W1MN
XHKG:2325 chart
P/E
—
P/S
—
EPS
0.00
Vol. 1Y
—
Shs. 5Y
-0.93%
Rev. 5Y
-12.91%
Div Yld LY
—
Div Yld TTM
—
Revenues
601m
-15.52%
619,707,031676,983,3761,200,320,0001,696,740,0003,756,201,000891,500,000711,884,000601,388,000
Net income
3m
P
-51,346,761-30,918,516255,334,000380,932,000377,309,000-102,259,000-791,682,0002,920,000
CFO
302m
+16.52%
64,551,342-8,088,226203,084,000369,459,000137,365,000333,843,000258,840,000301,613,000
Dividend
Jul 04, 20240.02 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Yunkang Group Limited, established in 2008 and headquartered in Guangzhou, People's Republic of China, operates as a comprehensive provider of medical operational services. The company offers a wide range of diagnostic testing solutions to medical institution alliances, which encompass assisting with the setup and enhancement of diagnostic centers, developing standard operating procedures for testing, delivering expert diagnostic consultations and staff training, sourcing necessary equipment, implementing smart Internet of Things technology, and providing logistics support. For diagnostic outsourcing, Yunkang Group conducts diverse tests, including pathology examinations; infectious disease diagnostics for conditions such as hepatitis B, tuberculosis, human papillomavirus, Epstein-Barr virus, rabies, and respiratory pathogens (via nucleic acid testing); genetic and reproductive health screenings; and routine diagnostic assessments for chronic ailments like kidney, blood, autoimmune, and endocrine metabolic diseases. Furthermore, the company caters to financial institutions and insurance firms by offering personalized diagnostic testing, medical report interpretation, and hospital referral services. Yunkang Group's capabilities also extend to information technology, medical logistics, procurement of medical equipment, healthcare technology development, and various project investments. These services are delivered through its network of independent clinical laboratories and integrated on-site diagnostic facilities.
IPO date
May 18, 2022
Employees
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT